GLPwatch
Wegovy for Obstructive sleep apnea
semaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCWegovy (semaglutide) is not FDA-approved for obstructive sleep apnea, and any use for this condition is off-label or investigational. A meta-analysis on semaglutide’s safety profile did not specifically evaluate its effects on obstructive sleep apnea.
AI summary of the sources below.
| Drug | Wegovy (semaglutide) |
|---|---|
| Condition | Obstructive sleep apnea |
| Approval status | Investigational / off-label |
| Research papers | 10 |
Wegovy is not FDA-approved for obstructive sleep apnea; the research below reflects investigational or off-label study only.
Research on semaglutide for obstructive sleep apnea (10)
- Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study.
- A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data.
- Evaluating the safety profile of semaglutide: an updated meta-analysis.
- Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Real-World Evidence.
- Comparative effectiveness of semaglutide <i>versus</i> liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis.
- An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review.
- Semaglutide: A New Medical Swiss Army Knife?
- Semaglutide 2.4 mg in French people living with Class 3 obesity and comorbidities: Baseline characteristics and real-world safety data.
- Semaglutide and GLP-1 Agonists: Forensic and Medicolegal Implications.
- Semaglutide and Tirzepatide for the Treatment of Obesity and Weight-Related Comorbidities: A Narrative Review.